Send to

Choose Destination
Cancer Med. 2019 May;8(5):2104-2113. doi: 10.1002/cam4.2097. Epub 2019 Apr 10.

Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.

Author information

Department of Hematology, Peking Union Medical College Hospital, Beijing, P.R. China.


Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD-1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune-associated medicine on PD-1 (+) cells. Gene expression profiling (GEP) was performed on circulating PD-1 (+) cells from 22 PTCL patients and 13 healthy subjects, and circulating PD-1 (-) cells from 2 PTCL patients. PD-1 (+) cells were treated with chidamide, and the production IFN-γ and cytotoxicity were analyzed. GEP were performed on circulating PD-1 (+) cells from 2 PTCL patients treated with chidamide combined with chemotherapy and 1 patient treated with traditional chemotherapy. GEP showed that genes associated with innate immune response were abnormally expressed in PD-1 (+) cells of PTCL patients compared with healthy subjects, meanwhile the expression of CTLA-4 was significantly higher in PD-1 (+) cells than that of PD-1 (-) cells. In vitro study revealed decreased level of IFN-γ secretion and impaired cytotoxic activity of PD-1 (+) cells compared with PD-1 (-) cells, while chidamide could recover the deficiencies and upregulate adaptive immune-associated genes in PD-1 (+) cells of PTCL patients. Our research indicated that PD-1 (+) cells might have deficiencies in innate and adaptive immune response and chidamide may reverse the defects.


adaptive immune; chidamide; innate immune; peripheral T-cell lymphoma; programmed cell death-1

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center